Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Deals

Glenmark Divests API Company, Setting Out On Distinct Journeys

Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”

Commercial M & A

Takeda Pens Mid-Trial Settlement To Dismiss US Colcrys Antitrust Suit

Japanese originator Takeda has agreed to settle two-year-old anticompetitive claims lodged by wholesalers in the US that it conspired with several generics manufacturers to maintain supracompetitive pricing for its Colcrys branded treatment for gout.

Legal Issues Deals

Abbott To Take mAbxience Biosimilars To Emerging Markets From 2025

European biosimilars specialist mAbxience will hand several of its biosimilars over to the global commercialization expertise of Abbott under a new agreement signed between the firms.

Biosimilars Deals

Amgen’s $27.8bn Horizon Takeover Stipulates Biosimilar Restrictions

The FTC’s proposed consent order allowing Amgen to move ahead with its mammoth takeover of Horizon includes an interesting stipulation for industry – one involving biosimilars.

M & A Deals

Dr Reddy’s Is Latest Rumored Buyer For Biogen’s Biosimilars

With Biogen having put its biosimilars interests on the market, multiple bidders appear to be interested in the business. Dr Reddy’s has become the latest firm to be named in media reports as vying for a deal.

Deals M & A

Lupin And Mark Cuban Shake Hands On Spiriva Alliance In US

Self-labelled ‘disruptor’ Mark Cuban has brought on board yet another high-demand prescription drug, following a recent deal for biosimilar Humira.

Deals Generic Drugs

Intas Rumored As Another Suitor For Biogen’s Biosimilars Business

Reports have named Intas as another possible buyer for Biogen’s biosimilars business, following earlier rumors that Samsung Bioepis could be interested in a deal. Generics Bulletin spoke to both Intas and Biogen for their reaction.

Deals M & A

Beyond Viatris: Kiran Mazumdar-Shaw Talks Next Steps For Biocon Biologics

As Biocon Biologics completes its integration of the biosimilars front-end business that it acquired from former partner Viatris, Biocon founder and chairperson Kiran Mazumdar-Shaw talks to Generics Bulletin about how the firm is now capturing the full value of its biosimilars, while also looking at expanding into new markets previously unserved by Viatris.

Biosimilars M & A

Sandoz Fills Pipeline Gap With Samsung Bioepis’ Ustekinumab

Sandoz has filled a gap in its biosimilars pipeline by in-licensing Samsung Bioepis’ SB17 ustekinumab biosimilar to Stelara, for commercialization in multiple global markets.

Deals Biosimilars

More Interest In Speculated Cipla Stake Sale: Portfolio, Cultural Fit Will Matter

After PEs, Torrent Pharma is speculated to be in the fray for a stake in Cipla. Experts weigh in on the contours of the product and cultural alignment of the two firms, should things move forward and also whether other Indian players could take a shot at the 'once in a lifetime opportunity'.

Deals M & A

Biocon Biologics Moves Quickly To Integrate Viatris In North America

Biocon Biologics has announced the latest milestone in its integration of former partner Viatris’s biosimilars business, completing the move in the US and Canada “ahead of schedule.”

M & A Biosimilars

Teva Settles On US Vivitrol Despite Conclusion Of Patent-Litigation Trial

Teva potentially was only a matter of days away from hearing a decision in its patent litigation battle over Vivitrol (naltrexone) long-acting injectable, but has instead put pen to paper on a settlement deal.

Deals Intellectual Property

Sandoz Offers Further Financials Ahead Of Spinoff

With around a month to go until Sandoz is expected to become a standalone company following its spinoff from parent Novartis, the firm has published additional financial information ahead of a shareholders meeting in mid-September.

Strategy Deals

Mallinckrodt Second Bankruptcy Plan Takes Axe To $1.7bn Opioids Fund

Just three years after its first, Mallinckrodt has entered into another restructuring support agreement with its debt holders and opioids trust, which will be facilitated by Chapter 11 bankruptcy proceedings in the US.

Financing Legal Issues

Sandoz Completes Deal For Mycamine

Just weeks before Sandoz completes its separation from parent firm Novartis, the company has completed a deal for worldwide rights to the Mycamine antifungal brand from Astellas.

Deals Strategy

CVS Lines Up Sandoz’s Adalimumab Biosimilar For US Biosimilars Subsidiary

CVS feels its newly launched, wholly owned US biosimilars subsidiary called Cordavis is a “logical evolution for us and will help ensure sufficient supply of biosimilars in the US and support this market now and in the future.”

Biosimilars Deals
See All